Many pharma companies chase advanced AI without solving the foundational challenge of data integration. With only 10% of firms having unified data, true personalization is impossible until a central data platform is established to break down the typical 100+ data silos.

Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.

Customers interact with a company as a single entity, but internally, separate departments like sales and support optimize for their own conflicting metrics. This creates a confusing and inefficient experience, a direct result of Conway's Law in action.

Go-to-market success isn't just about high-performing marketing, sales, and CS teams. The true differentiator is the 'connective tissue'—shared ICP definitions, terminology, and smooth handoffs. This alignment across functions, where one team's actions directly impact the next, is where most organizations break down.

Companies invest heavily in data but struggle to extract actionable insights. Different business units use disparate data sets, leading to conflicting signals and preventing cohesive, enterprise-wide commercial strategies. The goal is to find the "signal" in the "noise."

In pharma, one function's celebration is another's starting point. The regulatory team celebrating a successful dossier submission is a huge milestone for them, but for the market access team, it's the beginning of an arduous journey, highlighting a fundamental disconnect in goals.

The term 'retention team' inherently creates a silo separate from acquisition. A more effective approach is reframing all marketing functions as part of one 'customer team.' This mindset shift focuses everyone on the entire journey, from 'entering the door' to 'staying in the house.'

When patient engagement is owned by a single department, it's often treated as optional. To make it a core business driver, responsibility must be shared across R&D, medical, regulatory, and commercial teams. This requires a structural and cultural shift to become truly transformational for the organization.

Organizing by function (e.g., all sales together) seems efficient but incentivizes teams to optimize their individual metrics, not the company's success. This sub-optimization prevents cross-functional learning and leads to blame games, ultimately harming the entire customer value stream and creating a non-learning organization.